Grace Therapeutics, Inc. (GRCE)

Grace Therapeutics' stock (GRCE) has fluctuated over the past six months. As of November 26, 2025, the stock price was $3.21, with a 52-week trading range between $1.75 and $4.96. The stock price decreased by 4.75% over the last 12 months and showed a year-to-date return of -14.17%, but increased by 0.63% in the past month. Key events include participation in conferences, announcement of financial results and business updates, securing funding through warrant exercises, presentation of trial data at meetings, and being granted a U.S. Patent.

Demand for Grace Therapeutics' products is primarily driven by medical need and regulatory approvals rather than seasonal patterns, given its focus on rare and orphan diseases. There is no indication of demand seasonality for Grace Therapeutics' products or services.

Grace Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for rare and orphan diseases. Their lead product candidate, GTx-104, is for aneurysmal subarachnoid hemorrhage (aSAH). They are also developing GTx-102 for Ataxia-Telangiectasia (A-T) and GTx-101 for postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name in October 2024.

Grace Therapeutics is headquartered in Princeton, New Jersey, United States, and is involved in the development and commercialization of pharmaceutical products in Canada. Its lead clinical assets have received Orphan Drug Designation from the FDA, granting seven years of marketing exclusivity in the United States. The company's transition to a Delaware corporation was intended to enhance its appeal to global institutional investors.

Grace Therapeutics' brand reputation has been shaped by its corporate rebranding from Acasti Pharma Inc. in October 2024. This change aimed to reconnect the company with its scientific innovation roots. Public communications have focused on positive clinical trial developments and financial updates, with no reported negative events impacting its reputation in the past year.

Grace Therapeutics has a diverse ownership structure. Institutional investors hold between 6.08% and 26.23% of the company's stock, with major holders including Nantahala Capital Management LLC and Vanguard Group Inc. Individual and insider ownership accounts for approximately 49.85%, with Grace 2018 Irrevocable Trust Rajitha being the largest individual shareholder.